Oculus Innovative Sciences Announces Proposed Public Offering of Common Stock and Intention to Repay Certain Indebtedness Mar 6, 2013
Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With Issuance of U.S. Patent for Treatment of Skin Ulcers With Microcyn(R) Technology Feb 25, 2013
Oculus Innovative Sciences Reports Revenues of $3.5 Million for the Third Quarter of Fiscal 2013 Feb 13, 2013
Ruthigen, Inc., Subsidiary of Oculus Innovative Sciences, Inc., Appoints Sameer Harish as Chief Financial Officer Feb 5, 2013
Oculus Innovative Sciences Announces Fiscal Third Quarter 2013 Financial Results and Conference Call Jan 31, 2013
Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With Issuance of U.S. Patent for Treatment of Skin Ulcers With Microcyn(R) Technology Dec 27, 2012
In Preparation for European Partnership, Oculus Innovative Sciences Expects Expanded Label Claim for European Formulation of Dermacyn(TM) Wound Care Dec 24, 2012
